Filip Janku Sells 30,000 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 30,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $21.42, for a total transaction of $642,600.00. Following the completion of the transaction, the insider directly owned 59,992 shares of the company’s stock, valued at approximately $1,285,028.64. The trade was a 33.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total transaction of $239,505.90.

Monte Rosa Therapeutics Trading Up 2.9%

GLUE stock opened at $22.28 on Friday. The stock has a market cap of $1.88 billion, a PE ratio of -15.05 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 12 month low of $4.12 and a 12 month high of $25.77. The company has a 50-day moving average price of $18.96 and a 200 day moving average price of $18.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Sell-side analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. lifted their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Guggenheim reduced their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Finally, Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GLUE. GAMMA Investing LLC acquired a new stake in Monte Rosa Therapeutics during the 4th quarter valued at approximately $30,000. Nisa Investment Advisors LLC increased its stake in shares of Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth $63,000. Finally, Russell Investments Group Ltd. acquired a new position in Monte Rosa Therapeutics during the third quarter valued at $32,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.